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Abstract
Background: Clinical practice guidelines (CPGs) are common tools in policy and clinical practice informing clinical
decisions at the bedside, governance of health facilities, health insurer and government spending, and patient
choices. South Africa’s health sector is transitioning to a national health insurance system, aiming to build on other
primary health care initiatives to transform the previously segregated, inequitable services. Within these plans CPGs
are an integral tool for delivering standardised and cost effective care. Currently, there is no accepted standard
approach to developing, adapting or implementing CPGs efficiently or effectively in South Africa. We explored the
current players; drivers; and the context and processes of primary care CPG development from the perspective of
stakeholders operating at national level.
Methods: We used a qualitative approach. Sampling was initially purposeful, followed by snowballing and further
sampling to reach representivity of primary care service providers. Individual in-depth interviews were recorded and
transcribed verbatim. We used thematic content analysis to analyse the data.
Results: We conducted 37 in-depth interviews from June 2014–July 2015. We found CPG development and
implementation were hampered by lack of human and funding resources for technical and methodological work;
fragmentation between groups, and between national and provincial health sectors; and lack of agreed systems for
CPG development and implementation. Some CPG contributors steadfastly work to improve processes aiming to
enhance communication, use of evidence, and transparency to ensure credible guidance is produced. Many
interviewed had shared values, and were driven to address inequity, however, resource gaps were perceived to create
an enabling environment for commercial interests or personal agendas to drive the CPG development process.
Conclusions: Our findings identified strengths and gaps in CPG development processes, and a need for national
standards to guide CPG development and implementation. Based on our findings and suggestions from participants, a
possible way forward would be for South Africa to have a centrally coordinated CPG unit to address these needs and
aspects of fragmentation by devising processes that support collaboration, transparency and credibility across sectors
and disciplines. Such an initiative will require adequate resourcing to build capacity and ensure support for the delivery
of high quality CPGs for South African primary care.
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Background
Since the first democratic elections in South Africa in
1994, there have been many initiatives aiming to trans-
form the previously segregated and fragmented health
sector [1, 2]. These include integrating the public
health system at national level, shifting from racialised
to integrated health departments; introducing a re-
engineered primary health care (PHC) approach deliv-
ered through health districts; and, refocusing funding
to priority programmes such as immunisation and HIV
care [3]. Despite this, and the allocation of 8.5% of
gross domestic product (GDP) to health care provision;
South Africa’s health outcomes are relatively poor when
compared to other middle-income countries with simi-
lar GDP percentage expenditure on health [1, 3, 4]. In
the public sector, inequalities in healthcare delivery and
outcomes persist between urban and rural settings and
within and between provinces [5]. In response to this
inequality and the high burden of disease from commu-
nicable and non-communicable causes, and violence
and injury; the Minister of Health is driving forward
plans for universal health coverage (UHC), as described
in the National Health Insurance (NHI) White Paper
[6–9].
Quality of health service delivery must be of high
standard for UHC to achieve its intended goal [10–12].
Clinical practice guidelines (CPGs) are a common
knowledge translation tool in policy and practice, cov-
ering clinical decisions at the bedside, governance of
health facilities, health insurer and government spend-
ing, and patient choices. CPGs summarise rigorously
gathered evidence, distilled for use by healthcare pro-
viders to standardise and provide best-available care
[13, 14]. Within the range of operational tools available
for policy implementation, CPGs are recognised as cen-
tral to clinical service delivery [15, 16].
The South African government has introduced sev-
eral PHC quality improvement programmes, including
appointing District Specialist Clinical Teams (DSCTs)
to support services within health districts. The ‘Ideal
Clinic’ programme was initiated in 2013 to systematic-
ally consider and ensure adequate infrastructure, hu-
man resources, good governance and equipment for
primary care [8, 17]. This programme is governed by
specific clinical policies, protocols and CPGs, and aims
to involve stakeholders across government depart-
ments, the private sector and non-governmental orga-
nisations (NGOs) to address health and social needs. In
part, the intention is to integrate the preventative and
curative health services in a patient-centred manner
[18]. The ‘Ideal Clinic’, based on PHC principles, in-
cludes the Integrated Clinical Services Management
programme, which focuses on efficient, cost-effective
chronic disease management [17, 19]. In this context,
CPGs are specifically used as clinical training tools for
the DCSTs, and as part of clinical audit criteria to as-
sess a facility’s attainment of ‘Ideal Clinic’ status [17].
South Africa has long contributed to CPG develop-
ment with key players such as the National Depart-
ment of Health (NDoH), clinical professional
societies and NGOs producing guidance for their
respective constituents. In particular, the NDoH’s
Essential Drugs Programme has been producing guid-
ance documents since the mid-1990s to support
equitable use of medicines in the public sector.
Other research on CPG development has been con-
ducted in South Africa, in particular, exploration of
policy development processes for maternal health and
there has also been a quantitative evaluation of the
quality of CPGs for PHC [20–23]. What is lacking,
however, is comprehensive information on the pro-
cesses, context and challenges for PHC CPG develop-
ment and implementation in South Africa. The NHI
system will require agreement and integration across
sectors and jurisdictions, and national CPGs will
need to speak to healthcare needs of all to ensure
equal service delivery and redress of ongoing ‘fault
lines’ in the system [5]. This transition from the
current health system arrangement to NHI provides
a window of opportunity to explore the current ‘state
of play’ of CPG development and implementation in
order to inform NHI processes.
Currently, there is no available guidance on standard
approaches to developing, adapting or implementing
CPGs efficiently or effectively in South Africa. To ad-
dress this gap, the South African Guidelines Excellence
(SAGE) project was established as a multi-partner re-
search initiative aimed at setting in motion a
stakeholder-driven process to contribute to the under-
standing of standards of national CPG development,
adaptation and implementation [24]. The project con-
sists of several components, including a mapping phase,
development of an online CPG resource, and capacity
building opportunities for those involved in CPG devel-
opment, implementation and research. During the
mapping phase, a cross-sectional analysis of a sample of
16 PHC CPGs was completed, identifying the strengths
and gaps, in relation to global standards for CPG
reporting [23, 25]. We found that overall AGREE II
scores were poor to moderate, mostly due to poor
reporting of rigour of methodological approaches; ap-
plicability; and, editorial independence. These findings
are of concern as they may impact on the credibility of
South African CPGs. In this paper we examine these is-
sues in more depth by identifying the current role
players; drivers; and the context and processes of PHC
CPG development from the perspective of national
stakeholders [26].
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Methods
This research makes use of qualitative methods, drawing
on an interpretivist paradigm to explore national role
players’ experiences in the processes of developing and
implementing CPGs [26–28].
Research context
South Africa has a population approaching 55 million,
with a health system invested in primary healthcare and
district level ownership [8]. Fiscal federalism is in place
in which national government designs strategies, policies
and clinical CPGs; and provincial governments imple-
ment CPGs, sometimes after adaptation, to the levels of
healthcare from regional, district to community based
health centres [2]. Although government is responsible
for CPG development and implementation, many role
players contribute to CPG activities to fill clinical guid-
ance gaps, possibly duplicating, and possibly omitting
key health areas.
Sampling
Purposeful sampling began with consultations between
the research team and CPG developers known to have a
role in national CPGs [28]. Stakeholder groups included
the NDoH, academics and researchers, specialist profes-
sional associations, medical schemes, NGOs, and the
pharmaceutical industry. In addition, the five core
NDoH-endorsed primary care CPGs were identified:
Basic Antenatal Care, Integrated Management of Child-
hood Illness, the Essential Drug List (EDL) Standard
Treatment Guidelines for primary care and Primary
Care 101 (PC101), as well as a recently completed CPG
for Health Promotion and these were used to guide sam-
pling. We used a ‘snowballing’ approach in which a core
group of individuals actively involved with CPG develop-
ment or implementation in South Africa for primary
care were invited to participate; these individuals were
then asked to identify other ‘key role players’ for inclu-
sion in the sample [28]. During the course of the study
we recognised that some groups known to be involved
with PHC service delivery or linked with the endorsed
PHC CPGs had not been identified through snowballing.
At interim analysis, the sample was dominated by doc-
tors and pharmacists, thus, additional groups including
allied health, dentistry, nursing, and nutrition were pur-
posefully sought to fill gaps and achieve a satisfactory
degree of representivity [28]. Those interviewed occu-
pied senior managerial positions within government,
academic or organisations.
Data collection and management
Interviewers received training in semi-structured inter-
viewing techniques from a senior social scientist re-
searcher. All but one of the interviews were conducted
in pairs. Interviewers were all female and included vari-
ous professions including clinicians (medical doctors, al-
lied health professionals), social scientists and basic
scientists, all with previous interviewing experience, and
in analysis of qualitative data. The lead researcher,
present at most interviews, has experience, as a doctor
and specialist clinical pharmacologist, in using and
teaching CPGs. She is also known to some of those
interviewed and is involved with CPG activities at aca-
demic institutions and government which may have fa-
cilitated access to some interviewees, but could also
introduce response bias. For this reason, it was consid-
ered important to have two interviewers per interviewee,
one of whom who was not engaged in CPG activity, and
thus would have more distance so as to ensure
objectivity.
Invitations were emailed to potential participants
requesting a suitable time and venue for conducting
interviews. Participants were provided with informa-
tion sheets and consent forms prior to their interview.
We aimed to interview everyone in person, but four
participants requested telephonic interviews. Most par-
ticipants chose to be interviewed at their place of
work, with one exception who opted to do the inter-
view at home. Two of those invited referred us to other
colleagues to interview. None of those invited dropped
out or requested to withdraw once we started. Inter-
views lasted 60 min on average (ranging from 40 to
90 min). One interview was spread over two sessions
due to time constraints during the first meeting. Before
commencing, the focus of the project and purpose of
the interview were discussed, and consent was re-
affirmed, thereby ensuring that participants under-
stood clearly why they were selected, what the
interview was about and what their rights were. The
semi-structured interview guide (see Additional file 1)
was tailored to the experiences of each interviewee and
each interview built on the findings of previous inter-
views. In other words, as the interviews progressed, as-
sumptions, queries, and gaps in the evolving data set
were clarified through further data collection. Data sat-
uration was achieved prior to final interviews. The
additional 10 interviews were conducted to ensure a
representative sample and that no new themes
emerged.
Interviews were recorded using a digital recorder. All
interviews were transcribed by a third party, blind to
the aims of the study. Transcriptions were reviewed
for accuracy by members of the research team, but not
by those interviewed, making changes as needed based
on the audio files. Data is stored electronically on
password-protected computers; a masterlist and the
consent forms are stored in a locked cabinet to which
the study lead has access.
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Analysis
An iterative, thematic content analysis approach was used
[29]. A team of four, initially deductively, read the first 24
transcripts to develop a coding list, maintaining a focus on
the key research objectives, that is: players, process, con-
text, drivers and barriers to CPG development or imple-
mentation [26]. Once this coding list was developed, a
single researcher coded the remaining 13 transcripts inde-
pendently. Coding lists were categorised by identifying
common themes within the broad research question. All
preliminary findings were presented and discussed with
the team to verify further emergent themes at regular in-
tervals until all interviews and analysis were completed
(Additional file 2). A summary of the findings and emer-
ging themes were presented to the larger project team –
consisting of people who have experience in CPG develop-
ment, PHC service delivery, and the South African health-
care context - for validation.
Rigour
To ensure rigour [27], we initiated the project ensuring
the question was relevant. Our study may be of inter-
est to the national policymakers or other researchers,
and given the paucity of information on CPG activities
in middle or lower income settings generally, this may
have global relevance. We ensured validity through de-
tailed description of our approach to sampling, data
collection, data management, analysis. We considered
reflexivity as described in the methods and limitations
of the manuscript. The results are most transferable to
the South African context – where history and politics
have impacted on policy development. However, some
findings may be transferable to other developing coun-
try settings where transparency and CPG processes are
also in transition. There may also be transferability
within South Africa and learning from primary care
CPGs to other CPG development.
Ethics and reporting
The study was approved by the Research Ethics Com-
mittees of the South African Medical Research Council
(EC002–2/2014) and Stellenbosch University (N14/02/
008). All participants provided written informed con-
sent. Names of participants were anonymised, however,
it was explained to participants that despite efforts to
maintain anonymity, their opinions might be recognisable
in the reporting process. An opportunity for them to with-
draw before or during the interview was provided (none
took this opportunity), and to review how their opinions
were conveyed in the final manuscript (some took this op-
portunity). We referred to the Consolidated criteria for
reporting qualitative research (COREQ) reporting guide-
lines to ensure comprehensive reporting [30].
Results
Overall, CPG development is a complex web of interac-
tions between players and organisations, informed by
values, politics and power. Values reported include dis-
tributive justice, standardising care and equitable access
to medicines. The process for CPG production differs by
setting and group and is often poorly articulated. Silos of
guideline activity, both nationally and provincially, po-
tentially result in duplicated efforts for the often volun-
teer teams of technical experts. There is recognition of a
transition to more robust processes in some CPG devel-
opment groups. There is also recognition and accept-
ance of the need to improve further to align with
international standards; however, the financial and hu-
man resources are lacking.
We conducted 37 in-depth interviews with high-level
policymakers and CPG contributors from national and
provincial Departments of Health; professional societies;
for-profit groups including pharmaceutical industry and
medical schemes; university academics; funders and
technical advisors (Table 1).
Role players in CPG development
Public sector players
Those interviewed agreed that NDoH plays the central
role driving and developing guidance documents
through their various directorates, supported by part-
ners, including academic institutions, funders and tech-
nical advisors from multi-lateral organisations such as
the WHO and UNICEF.
Guidelines is a big national Department of Health role
… [INT06].
It’s the government who is pushing, the government
which defined the date, the approach and so on and
Table 1 Description of stakeholders sampled (37 total)
Background discipline Medicine (19), pharmacy (5), nursing (4), allied health (3),
dentistry (1), nutrition (2), non-clinical managers (3)
Provinces represented Eastern Cape (1); Gauteng (16); Kwazulu-Natal (3); Western Cape (17)
Sectors and stakeholder
groups
National (10) and Provincial Department of Health (2); Professional Societies (6);
Private sector (pharmaceutical 1; and medical Schemes 2) (3); academia (14);
non-governmental organisations (2)
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as part of development partners, we go there to help.
[INT23]
Within government there is a central programme devel-
oping CPGs particular oriented to the essential medi-
cines list which is linked with streamlining national
medicine and device procurement; and in parallel there
are disease or topic specific programmes, such as HIV,
tuberculosis, rehabilitation and nutrition, developing
CPGs, with potentially overlapping content.
In addition to the NDoH CPG development efforts,
medical schemes, professional societies, at times with
pharmaceutical industry support, NGOs, provincial hos-
pital or clinic level initiatives all develop CPGs where no
or limited guidance exists. Participants, generally aca-
demics from outside of government, suggested that their
role in CPG development emerged to address gaps in
clinical guidance, not covered by NDoH.
But then some of the smaller, neglected diseases don’t
have a directorate at the Department of Health or
whatever ... And so often those are undertaken by
professional societies [INT06]
Organisations like the TAC [Treatment Action
Campaign] that has driven the engagement and
enabled professionals to actually engage with
government and get good policies in place and develop
good guidelines [INT18]
Furthermore, while PHC providers such as nurses play
the central role in service delivery at PHC they are not
seen to be driving CPG activities nationally, and were
described as noticeably absent in leading roles except
perhaps in consultation processes or external review of
documents.
Private sector players
Private health insurance is an important player in clin-
ical care in South Africa. Funding of medicines and de-
vices is decided through advanced systems and
committees within each scheme. Insurers are governed
by the Council for Medical Schemes who develop the
prescribed minimum benefit packages - however, up-
dates to these have not been promulgated for more
than a decade. Some participants described how the
essential medicines programme should form the basis
of the prescribed minimum benefit and ideally, align-
ing private sector with national government.
Ultimately the view is to change the legislation with
regard to private health care to make sure that this
essential medicines list forms the basis of this
minimum benefit package and then you remove a
whole bunch of inequity out of this private health
insurance [INT11]
At the end of the day, as we go into an NHI, this
divide should not exist [INT14]
The pharmaceutical industry, another private player,
may contribute evidence to medical schemes, profes-
sional societies and government to encourage invest-
ment in their health technology. They provide grants to
support some professional society guideline develop-
ment. Beyond the guideline development they impact
pricing of medicines, and influence practice of clinicians.
We have over the years been very conscious of the role
and the influence of industry in shaping decision-
making, even within the various well-respected na-
tional societies [INT18]
Consulting end-users and external groups
Although NDoH aims to involve various sectors and
interest groups through workshops and consultation
during CPG development, the need for tangible engage-
ment from stakeholders was described as a key area for
improvement.
we had people from facilities, we had nurses at
different strata, you had unions and you had nurses
from facility level giving input to that scale-up plan
which is very specific and thus you can say a guideline
for getting your clinic to function optimally … we also
involve the civil society organisations, our donor part-
ners and the NGO’s that, we call them implementation
partners funded by the donor partners, and then other
government departments and also private sector orga-
nisations [INT27]
We tried, really tried by all means to involve all the
stakeholders because with just us alone we won’t be
able to, to reach you know everybody who really needs
to be involved in addressing that particular problem
… I do not think we have really found a better, you
know, a better mechanism of really, you know,
engaging the people who are, who are at the frontline
of implementation on how do you really want us to
package some of this document [INT37]
Values and drivers for CPG development
The dominant view expressed by participants was that
CPGs are valued for supporting delivery of standardised,
equitable healthcare, especially in the post-apartheid
South African context to ensure access for all to PHC.
CPG development was driven by the same complex in-
fluences as other health policies [31], despite different
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disciplinary and ideological backgrounds. According to
our participants the values included commitment to the
NDoH’s tagline “health for all” [INT04]; addressing his-
torical inequalities; and standardisation of quality and
cost-effective healthcare.
Driver: equity
The need for greater equity was raised in both public
and private sector interviews. As a function of govern-
ment, the NDoH’s Essential Drugs Programme, was
viewed as promoting change from the earlier fragmented
health systems arrangements and the principles of equity
of access to medicines [32].
the essential drugs programme basically brought
together all the formularies from the different
homelands throughout South Africa, and tried to
level the playing fields to make sure that there is
equity in the way medicines are made available and
accessible … So we don’t want that disparity between
provinces [INT16]
Contrary to this, the medical schemes legislative envir-
onment was reported to encourage competition rather
than collaboration which raised concerns regarding
how this may perpetuate inequity and inappropriate
spending.
And we need to make sure our policy is fair, transparent
and equitable within the context of the benefit designs
that are … there are a lot of anomalies in private
healthcare because it is hopelessly inequitable. Even the
legislation with regard to private health care coverage is
inequitable but we are sort of constrained within the
sort of legislative environment that we operate in. And
so we need to find a mechanism to be able to operate
properly within that [INT11]
Drivers: personal, fiscal or political interests
Although equity was a dominant driver, participants dis-
cussed the prevalence of personal, fiscal or political
values or agendas amongst academics, the pharmaceut-
ical industry or other commercial enterprises and inter-
national organisations. In addition, CPG development
was described as being driven by priorities of funders in-
cluding NGOs, international donors or industry for new
research or products.
One of the big issues … is who is driving its development
and why. And if you think about why people develop
guidelines, it’s actually the fact that a massive amount is
driven by industry, and then it’s driven by the needs to
some extent and personal interest to another extent.
[INT20]
Everybody brings a bias to the table and WHO is a
really sore point with a lot of our experts because
they’re writing policy for …. Africa right, they’re
writing public health policy ... If anybody should be,
we should be telling WHO what to do [INT08]
As CPG development is poorly funded, participants per-
ceived this as an opportunity for the pharmaceutical in-
dustry to fund development through unrestricted
educational grants, which in turn may undermine the in-
dependence and credibility of a CPG. However, this view
was not shared by all within academia and professional
societies, as in some cases limited funding and the needs
of constituents were valued above potential conflicts of
interest. It was also suggested bias was perceived as the
norm rather than the exception in CPG groups within
professional societies.
we are critically dependent on drug companies. No one
else is willing to fund guidelines. I mean, theoretically,
if one looked at it in its purest form, the department of
health should be funding all of this. They should be
intricately involved – we should all be doing it
together – but they don’t. They don’t at all [INT19]
Processes in place for CPG development
As we explored the deductive categories of players,
drivers, context and process of CPG development, sev-
eral sub-themes emerged including the perceived chal-
lenge of fragmentation of CPG development and
implementation processes; human skills and resource
shortages; and, gaps in standardised systematic methods.
Fragmentation: socio-political environment impacts CPG
processes
So all are little silos inside other silos [INT20]
Participants described fragmentation affecting both
CPG development and implementation, with most
expressing concern regarding inefficient use of lim-
ited human and funding resources. Fragmentation oc-
curred between national departments, between the
private and public sectors, between national and pro-
vincial departments of health, between provinces and
within provinces and districts.
Fragmentation impacts development
The fragmentation within government programmes,
and between the public and private sectors is de-
scribed as predominantly affecting CPGs production.
Silos within NDoH processes, where individuals work
in closed teams, not communicating effectively across
departments, teams or working groups, were thought
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to result in duplication, poor resource use and gaps
in recommendations. For example participants ex-
plained that directorates may produce parallel guid-
ance to that produced by another group or
professional society. Some participants described im-
proving coordination of CPG development processes,
however, not consistently or universally. The slow
progress in addressing known issues of fragmentation
was attributed to the limited capacity (administrative,
organisational) and inadequate financial resources
from central government.
There is nothing in the department of health that
will take on community acquired pneumonia
guidelines. Where does it fall? It doesn’t fall into any
directorate. So the societies have traditionally done
this [INT06]
Poorly coordinated national CPG development is per-
ceived to have knock-on effects as healthcare providers
receive conflicting guidance, in turn hampering
implementation.
Fragmentation impacts implementation
Participants described a disconnection between na-
tional and provincial government, suggesting this re-
sulted in CPGs which lacked legislative power to
enforce standardised implementation and impact ser-
vice delivery. These responses reflects South Africa’s
fiscal federal-oversight system, in which national gov-
ernment develops policies and provinces have inde-
pendence to implement [33]. This form of governance
may perpetuate disparity between provinces, however,
there is recognised complexity given that each prov-
ince has different infrastructure, governance strengths
and capacity to adapt and implement policies.
the whole national - provincial problem is a huge
issue that this country has to kind of sort out …
There is incredible frustration in that they [National
Department of Health] don’t have the power and the
provinces can kind of, they may say sort of set this
policy but they can’t enforce it and no one is
reporting, there’s no accountability [INT08]
Despite concerns about differences between provinces,
global best practice suggests that CPGs should be
adapted to local contexts. South African provinces have
vastly different contexts, including resources, cultures,
and infrastructure that require context-specific adapta-
tions. Thus, as expressed by some, there is an inherent
tension in trying to develop CPGs as national standards,
when needs might demand different regional or district
approaches.
Resource shortages: human capacity and time
Most participants expressed anxiety about lack of tech-
nical skills, dedicated time and funding for quality CPG
development. This perceived ‘insurmountable task’ was
thought to have a knock-on effects resulting in chal-
lenges with transparency and falling short of inter-
national standards.
I sympathize with the department on a lot of levels
because they don’t have the resources, they’re
constantly fighting fires but now it’s just not
appropriate anymore to have this, policy making
should be transparent, it should be thought through, it
should not be something done hurriedly [INT08]
As soon as you look at this process it becomes almost
insurmountable. Essentially, what is international
consensus on how it should be done, and then the reality
is that there’s just a mass of work to be done to combat
that load to be correct, even if you were just to perhaps
redevelop from scratch, which is something you should
probably do. And there probably isn’t the resources
either in-house, or even if you were to spread it out, to
get everything up and running at the same time [INT20]
Human capacity shortages
Of the limited human resources, medical doctors ap-
peared to dominate the national primary care CPG de-
velopment groups, followed by pharmacists; with other
disciplines working in parallel within different govern-
ment directorates. Nurses were generally not part of na-
tional guideline groups.
You know, there are very few people who can actually
develop the guidelines from nursing. Very few people
have that expertise – almost no one [INT18]
Many individuals interviewed mentioned that volunteer
clinical experts and members of guideline groups had
multiple roles over and above their usual positions. They
were often tasked with methodological work of search-
ing for, appraising and synthesising evidence. The same
experts may also be involved with CPG design and
implementations. Some recognised this as a weakness,
while others accepted this as the reality of low-resource
environments.
So they go through a lot of, it’s a lot of work, first of
all, people who are doing other jobs [INT06]
Lack of skills transfer in guideline groups
CPG development was seen by some as being dominated
by the same individuals often included in CPG panels
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over many years. Limited capacity was felt to be, in part,
a consequence of poor succession planning within
government.
I mean, you know, some of these folks have been
involved forever [INT08]
Some participants suggested that this hampered a hand-
over of skills. More inclusive CPG panels were desired
as an opportunity for ‘on the job’ capacity building, but
at times, experienced members were lost prior to new
members being adequately capacitated. Some partici-
pants were encouraged by the addition of new panel
members – which they viewed positively as allowing the
development of more transparent, inclusive processes.
Conflicts of interest: funding drives agenda
Participants suggested that when skills to conduct the
necessary technical work are deficient, groups with fi-
nancial or other vested interests, often linked with
pharmaceutical industry, may use the opportunity to
drive their interests for marketing their health technolo-
gies. A lack of capacity to synthesise evidence could re-
sult in a reliance on the industry for support.
Pharmaceutical players have resources to package evi-
dence or fund CPG activities. The implication is due to
the resource shortages described the industry may exer-
cise their influence.
Now that process is terrible because a lot of the
clinical colleagues do not have the skills to put an
evidence based discussion together, so that’s where a
lot of the conflict comes in. They get the industry to
write them [INT01]
Gaps: lack of systems for CPG development
No standardised processes for development
CPG development is not uniformly organised within the
different NDoH programmes.
It’s chaotic, it’s uncoordinated, it’s opaque [INT08]
Participants suggested some programmes had structured
systems while other programmes’ processes were per-
ceived as “ad-hoc” or “chaotic” or in the case of private
sector, guided by outdated protocols.
Well, I don’t know what happens. They seem to be like
a complete black box [INT03]
told by the minister, you know, like we need these
guidelines out immediately. And then you’ll get stuck
into it, and then there will be a new HoD [head of
department], and then there will be a new this and
there will be a new that. You know, the process is just
very, very chaotic locally [INT14]
For instance, like the PMB [prescribed minimum
benefit] guidelines, the algorithms are really a mess at
the moment. They were published 15 years ago or
whatever, and they are just a little one-pager with a few
little lines. And they were extensively updated five years
ago…. and they are still not promulgated. The private
sector is sitting in a vacuum because the medical aids
by law only have to fund to that level [INT18]
Some CPG development groups such as the NDoH
Essential Drugs Programme, established with good
intentions during the post-apartheid period, were
described as improving their processes over time; having
put in place rigorous CPG development approaches.
They were also criticised for poor communication and
lack of transparency in decision-making. This group has
explicit documents for ensuring interests are declared
and confidentiality respected [34]. What is not apparent
in the available documents is how transparency can be
improved and processes shared to build public trust.
Participants from outside government tended to have
less trust in the government processes due to unsatisfac-
tory experiences with trying to contribute to the CPGs
which seemed to lead to reluctance to buy-in from some
individuals and groups.
I mean the EDL seems like a very well-run process.
Now I mean I have issues with the EDL not being
transparent, I mean I think I would like to see mi-
nutes, I think as public sectors, you know, public funds
and that sort of thing, we’re entitled … [INT08]
And I think we have to really consider what the best
means is of documenting evidence and then sharing
that evidence in order to get buy-in [INT21]
Managing conflicts of interest
Our academic participants often held multiple roles,
both for government and their institutions. Those in-
volved with professional societies reported their desire
to collaborate with or be endorsed by government. Some
societies seemed to be successful in working with gov-
ernment or identifying independent funding to develop
CPGs, however, most were described to rely on pharma-
ceutical companies. Some members of professional soci-
eties were described as receiving funding from many
industry sources, but the processes for reporting or
managing these potential conflicts differed.
Everyone is going to have a conflict of interest, because
everyone is going to have to have received funding
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from someone for something ... So the answer is
probably yes, we should, but I think at the end of the
day it’s probably not practical [INT19]
Transition to better processes
Participants indicated that improvements are needed for
CPG development to meet global standards, however,
some reported that over the past 20 years there has been
slow but persistent progress and a shift to increasingly
transparent systems and methods for CPG development.
I think guidelines have come a long way, I think they’re
much more evidence based [INT06]
There’s a keen awareness that it could be done better
and that there should be some sort of debate [INT21]
The commitment of CPG developers to advance CPG
processes is an influential enabler of continued progress.
Implementation processes lag behind
Several participants complained that CPG implementa-
tion is lagging and requires additional specific skills and
adequate funding to ensure recommendations reach
end-users and contribute to improved patient outcomes.
in terms of guideline development there’s still a lot of
work that needs to be done, but in terms of
implementation there’s more work that needs to be
done [INT16]
For the most part, national CPG developers, had fewer
responses to questions regarding implementation, and
referred us to provincial players to explore this further.
Discussion
Global reporting for CPGs requires adherence to several
quality standards including a description of a clear scope
for the CPG; inclusion of all relevant stakeholders in de-
velopment; rigorous methods for finding and assimilat-
ing evidence; and ensuring conflicts of interest and
funders interests are recognised and managed [14, 35].
Yet there is evidence that South African CPGs fall short
of quality reporting standards [23, 36]. We sought to ex-
plore the reasons behind this through the perspectives
of national stakeholders regarding current processes,
drivers, enablers and barriers for primary care CPG de-
velopment. Our analysis suggests that the context and
processes for CPG development represent a complex
network of interactions, informed by values and power.
There are multiple stakeholders, across government de-
partments, healthcare disciplines, and sectors contribut-
ing to CPGs with varying skills and intentions. The
NDoH is the key role player in CPG development for
the public sector, with professional societies and other
organisations filling in gaps (i.e., topics where guidelines
do not exist, or in situations where guideline updates
have not been undertaken for a number of years). Des-
pite the common view that CPGs are valued for support-
ing delivery of standardised, equitable healthcare, there
is also a belief that CPGs may in some instances be
manipulated by commercial, personal or other interests.
CPGs aim to address health inequity as reflected in
the national policies and plans for PHC reform. CPGs
are specifically mentioned as useful tools to assist several
key programmes including the NHI and the ‘Ideal Clinic’
[15]. In light of the intended transition to UHC through
the proposed NHI funding system, private and public-
sector CPGs will need to be aligned to ensure equitable
access to quality healthcare services [7, 9]. In this con-
text, concerns were raised regarding the parallel private
and public healthcare system wherein private insurers
operate independently from national government. The
out-dated clinical protocols and Prescribed Minimum
Benefits packages mean that private sector funders have
freedom to drive healthcare decisions based on criteria
other than best evidence or cost-effectiveness. The
current proposal for NHI recognises this deficiency, and
proposes revision of the medical schemes Prescribed
Minimum Benefits and for health technology assessment
to underpin clinical recommendations [9].
Processes for CPG development in SA
The slow progress experienced in improvements in the
health system and the fact that issues like fragmentation
still persist has been highlighted in other health systems
research [5]. Despite the introduction of key health pol-
icy reforms [5, 37], historical issues like fragmentation,
human resource challenges and paucity of standardised
systems continue to hamper progress in all areas of
healthcare delivery [38]. Interviewees consistently re-
ported concerns about the fragmented health system
and its impact on CPG development and implementa-
tion. Fragmentation of CPG development may be under-
stood to reflect these longstanding weaknesses in
available systems resulting in opaque methods for CPG
development; possible duplication due to lack of central
oversight and communication between national CPG de-
velopment groups; under-resourcing of people with
specific skills to develop and implement CPGs; and, gaps
in feedback and communication systems between
stakeholders.
Several well-credentialed international groups have
developed standardised methods outlining key steps to
ensure trustworthiness of the final CPG [13, 39, 40]. We
found that no such guidance exists in South Africa, and
most interviewees described ad hoc processes, including
inadequate consultation, and poorly managed conflicts
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of interest which may result in biased CPG recommen-
dations, and diminished buy-in for CPGs [41]. These
deficits may, in turn, impact on implementation. Imple-
mentation particularly was an issue of the national-
provincial disconnect, however, only few of those
interviewed were closely involved with implementation
as this is largely the responsibility of provincial
government.
Lack of adequate Human Resources for Health is a
commonly reported problem in South Africa, particu-
larly in rural districts [2, 5, 42]. For CPGs, we found that
there is a limited pool of skilled contributors to CPG de-
velopment, who are often working voluntarily or for lim-
ited remuneration and are overburdened. The specific
technical skills gap identified includes capacity to syn-
thesise and incorporate evidence; regular communica-
tion on CPG processes with stakeholders; and design
and implementation for CPGs.
Limitations and strengths
Limitations of our study include potential for sampling
bias. Our sample is dominated by medical professionals,
many from Gauteng and Western Cape Provinces. Our
sample probably reflects the reality of skewed power dy-
namics in CPG development in South Africa, where
many who lead national knowledge production, and
therefore are able to contribute their voluntary time to
the process, may be based in the Western Cape and
Gauteng. To minimise and mitigate this potential bias,
we allowed for snowballing for any and all national con-
tributors to CPG processes; in addition, we purposively
sampled across all primary care disciplines. The skew
sample suggests that CPG development needs to become
more inclusive of different disciplines in different prov-
inces throughout South Africa. Another possible limita-
tion is response bias as those interviewed are all active
members in CPG development and likely to be positively
inclined towards the value of the work. Therefore, we
explored the players, drivers, processes and context ra-
ther than the perceived value of CPGs. Another potential
limitation is the impact of where researcher team mem-
bers are ‘situated’, their institutional affiliation, and per-
ceived credibility also called ‘positionality’ [31].
Positionality may facilitate gaining access to policy-
makers and discussion of sensitive issues and it may
allow for interpretation of nuanced cues, but may also
skew responses, similar to the Hawthorn effect [28, 31].
Generally one of the interviewers was from Cochrane
South Africa, a recognised specialist unit for evidence
synthesis. However, the senior experienced policymakers
and CPG contributors interviewed were thought to be
peer level to the interviewers and less likely to be influ-
enced by power dynamics commonly ascribed to inter-
viewer/interviewee relationships [28].
Our study also had several strengths such as the
teams’ prior training in qualitative interviewing; pre-
knowledge of the CPG context, augmented by speaking
to experts; the inclusion of members from different dis-
ciplines who could point to gaps in the process, thus en-
hancing rigour; and, reaching a range of participants,
including senior members of the NDoH.
What does it mean for SA CPG developers and development?
We found overwhelming commitment by those involved
and slow but consistent transition to improving systems
and processes. Commonly shared values regarding ad-
dressing inequitable clinical service through improved ac-
cess to medicines and care defined by good quality CPGs
may serve as an enabler to further processual improve-
ments. Based on our findings, we feel that the key areas
requiring attention include the need to reduce fragmenta-
tion by considering central coordination of CPG activities
with buy-in from public-private stakeholders and ongoing
communication between stakeholders already involved.
We recommend that this be underpinned by agreed na-
tional standards and processes for CPG development and
implementation, considering different provincial contexts.
Finally, we feel that resourcing of activities is key to de-
velop capacity to conduct methodological work, support
clinical recommendation decision-making using transpar-
ent processes and improve communication, dissemination
and implementation.
Conclusion
As South Africa transitions towards the NHI system and
the ideal of “health for all” there is an opportunity to re-
flect on lessons learned from PHC CPG contributors,
and build on global experience and knowledge. WHO’s
PHC Alma Alta Declaration states that PHC is a funda-
mental right and that ‘primary health care is essential
health care based on practical, scientifically sound, so-
cially acceptable methods and technology’ – in our con-
text, CPGs provide the bridge and process through
which this may happen [19]. However, South Africa is
among many countries with faltering progress in advan-
cing principles of WHO’s Alma-Ata for universal access
to PHC [19, 38]. The data suggests that the current par-
allel private-public health systems pose a substantial
challenge to uniform healthcare access. Participants de-
scribe commitment on the part of government, and
those who support government in their CPG endeav-
ours, to build collaborative, transparent, adequately
funded and staffed systems that foster communication
and encourage efficient use of the country’s scarce re-
sources. A national CPG coordination unit could assist
to develop credible, efficient structures to address the
challenges identified.
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